News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–50
Matches
50
Sources here
8
Companies here
1
Search results Stored financial headlines

Active search

50 matching headlines

Ticker or company: VSTMMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Deals and strategy Main company 🇺🇸 United States

Verastem Inc (VSTM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Verastem Inc.'s (VSTM) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and details multiple stock splits/mergers that occurred on May 31, 2023, with a ratio of …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Verastem Inc (VSTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Verastem Inc (VSTM). It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The article focuses on the current stock performance and mentions the …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Verastem Inc (VSTM) Cash Flow

This article provides an in-depth look at Verastem Inc.'s (VSTM) cash flow statements, including operating, investing, and financing activities, across quarterly and annual periods. It details various financial figures and year-over-year changes for items like net income, capital expenditures, and free cash flow. The …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Verastem Inc (VSTM), highlighting its current earnings forecast score, analyst ratings, and price targets. Based on 9 analysts, the average price target is $15.50, with a "Buy" recommendation. The report also includes expected revenue and EPS for …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Verastem Inc (VSTM) Institutional Confidence

Verastem Inc (VSTM) has an institutional shareholding score of 10.00, placing it first out of 386 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 95.00%, marking a 7.42% increase quarter-over-quarter. Key institutional shareholders include RTW Investments L.P., Deep Track …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Verastem, Inc. Revenue Breakdown – HAM:2VSA

Verastem, Inc. (HAM:2VSA) generated €26.32 million in revenue last year, primarily from its Drugs segment. The United States was the company's largest contributor, accounting for all of its revenue. This represents a significant increase from the previous year's revenue of €9.66 million.

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Verastem Inc. (VSTM) holder outlines potential sale of 31,924 common shares

A holder of Verastem Inc. (VSTM), Robert Gagnon, has filed a Form 144 notice indicating a potential sale of up to 31,924 shares of common stock through Jefferies LLC, with an aggregate market value of $188,032.36. The planned transaction date is July 23, 2026, …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Earnings Main company 🇺🇸 United States

Press Release: Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Verastem Oncology will report its second quarter 2026 financial results on August 6, 2026. The company will also provide a corporate update on that date. Investors and interested parties can access these updates through a press release and conference call.

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Earnings Main company 🇺🇸 United States

Verastem Oncology to report Q2 2026 financial results in conference call

Verastem Oncology is scheduled to report its second-quarter 2026 financial results and provide a business update on August 6, 2026, at 4:30 p.m. ET. The details will be presented during a conference call and webcast, with slides available on their investor relations website. This …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Verastem Oncology Schedules Aug. 6 Webcast for Business Updates

Verastem Oncology (Nasdaq: VSTM) has announced it will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 pm ET to discuss its second-quarter 2026 financial results and provide business updates. The event will be accessible via a live audio webcast …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Canada Market update Main company 🇺🇸 United States

Verastem doses first patient in lung cancer trial for VS-7375

Verastem Oncology has dosed the first patient in its TARGET-D 202 Phase 2 trial for VS-7375, targeting KRAS G12D-mutated advanced non-small cell lung cancer. This investigational oral inhibitor is designed to treat patients whose disease progressed after prior chemotherapy and anti-PD-(L)1 therapy, including a …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Regulatory and legal Main company 🇺🇸 United States

Verastem Starts VS-7375 Phase 2 Lung Trial at 900 mg Daily | VSTM Stock News

Verastem Oncology has dosed the first patient in its TARGET-D 202 Phase 2 trial for VS-7375, an investigational oral KRAS G12D inhibitor, targeting advanced non-small cell lung cancer (NSCLC) with KRAS G12D mutation. This trial is registration-directed, and a cohort will also investigate patients …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TipRanks Earnings Main company 🇺🇸 United States

Verastem Inc (VSTM) Q1 2026 Earnings Report - Results, Call & Slides

Verastem Inc. (VSTM) reported its Q1 2026 earnings, beating EPS estimates but missing on revenue. The company posted an actual EPS of -$0.37 against a consensus of -$0.47, with revenue of $18.67M versus an expected $21.43M. Key highlights include steady product revenue growth from …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
STAT Analyst action Main company 🇺🇸 United States

Redefining how KRAS G12D is targeted in cancer treatment

Verastem Oncology is pioneering a new approach to target the KRAS G12D mutation, which is prevalent in many cancers and traditionally difficult to treat. Their investigational drug, VS-7375, is a dual ON/OFF KRAS G12D inhibitor designed for durable pathway control, showing early anti-tumor activity …

VSTM main company
Sharemaestro market context Price above Trend Line 52 weeks -27.5% VSTM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context